Drug Profile
Atu 027
Alternative Names: Atu027Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Atugen AG
- Developer Silence Therapeutics; Silence Therapeutics AG
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action Protein kinase N3 inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Head and neck cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Head-and-neck-cancer in United Kingdom (IV, Infusion)
- 04 Nov 2017 Discontinued - Phase-I for Solid tumours (Late-stage disease) in Germany (IV)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Germany (IV, Infusion)